Outcomes after early treatment with hydroxychloroquine and azithromycin: An analysis of a database of 30,423 COVID-19 patients
Background: Many studies have evaluated the use of hydroxychloroquine in COVID-19. Most retrospective observational studies demonstrate a benefit of using HCQ on mortality, but not most randomized clinical trials. Methods: We analyzed raw data collected from a cohort of 30,423 patients with COVID-19...
Main Authors: | Philippe Brouqui, Matthieu Million, Philippe Parola, Peter A. Mccullough, Didier Raoult |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-10-01
|
Series: | New Microbes and New Infections |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2052297523001075 |
Similar Items
-
Cardiovascular Safety of Hydroxychloroquine–Azithromycin in 424 COVID-19 Patients
by: Matthieu Million, et al.
Published: (2023-04-01) -
Outcomes of 2111 COVID-19 Hospitalized Patients Treated with Hydroxychloroquine/Azithromycin and Other Regimens in Marseille, France, 2020: A Monocentric Retrospective Analysis
by: Lagier JC, et al.
Published: (2022-05-01) -
Impact of Azithromycin and/or Hydroxychloroquine on Hospital Mortality in COVID-19
by: Filippo Albani, et al.
Published: (2020-08-01) -
CLINICAL OUTCOMES AND ADVERSE DRUG REACTIONS IN COVID-19 PATIENTS TREATED WITH HYDROXYCHLOROQUINE AND AZITHROMYCIN ALONE OR COMBINED
by: H. Rathi, et al.
Published: (2021-11-01) -
Covid-19: Effects of Azithromycin/Hydroxychloroquine/Ivermectin in ambulatory and hospitalized patients
by: Henry Mejia-Zambrano, et al.
Published: (2021-10-01)